CITI-002
Acute respiratory distress syndrome (ARDS)
PreclinicalEarly-stage
Key Facts
Indication
Acute respiratory distress syndrome (ARDS)
Phase
Preclinical
Status
Early-stage
Company
About Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage biopharma company with a mission to develop and commercialize first-in-class critical care products. Its key achievement is the FDA approval and commercialization of LYMPHIR™ for cutaneous T-cell lymphoma, marking its transition to a commercial-stage entity. The company's strategy is built on a diversified pipeline targeting high-need areas like catheter-related infections and adjunct cancer care, with a core focus on accelerating promising therapies through late-stage development. Financially, it operates as a micro-cap public company, navigating the capital-intensive path of drug development while managing a lean operational structure.
View full company profileTherapeutic Areas
Other Acute respiratory distress syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| BXT-25 | BioXyTran | Preclinical |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| FX06 | F4 Pharma | Phase 1/2 |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| RP-323 | PhorMed | Phase 2 |
| Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS | Sedana Medical | Investigator-Initiated Trial |